# Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

> **NCT04064242** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 62 (actual)

## Conditions studied

- Pulmonary Sarcoidosis

## Interventions

- **DRUG:** CMK389
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04064242
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-23
- **Primary completion:** 2023-09-19
- **Final completion:** 2023-12-12
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04064242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04064242, "Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04064242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*